Overview

RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia

Status:
Terminated

Trial end date:
2003-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study was to determine if alternate dosing of Epoetin alfa was effective in maintaining hemoglobin levels in patients with chemotherapy related anemia.

Phase:

Phase 4

Details

Lead Sponsor:

Ortho Biotech Products, L.P.

Treatments:

Epoetin Alfa